Sarah Cannon Research Institute | Strategic Alliance Partners

Dr. Meredith Pelster sat down for an interview with CURE to discuss new data surrounding new treatment outcomes for metastatic pancreatic cancer.

Tukysa may be a patient-friendly option as a first line maintenance treatment for HER2-positive breast cancer, as Dr. Erika Hamilton explained.

Dr. Erika Hamilton spoke with CURE’s editor-in-chief, Dr. Joshua K. Sabari.

Dr. Erika Hamilton sat down for an interview with CURE’s editor-in-chief, Dr. Joshua K. Sabari.

Tukysa added to Herceptin and Perjeta improved progression-free survival versus placebo in HER2-positive metastatic breast cancer after initial therapy.

Breast cancer types, staging, diagnosis, treatment, and survivorship are complex, but understanding them helps patients make informed care decisions.

Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.

Dr. Erika Hamilton discusses the most notable breast cancer treatments currently in development, and how might they change care for patients in the future.